HOUSE BILL No. 5200

October 18, 1989, Introduced by Reps. Hertel, Harrison, Bartnik, Stabenow, Middaugh, Stacey, Oxender, Kosteva, DeBeaussaert, Pitoniak, DeMars, Bankes, Spaniola, Miller, Bennett, Randall and Law and referred to the Committee on Public Health.

A bill to amend sections 17401, 17412, 17708, and 17749 of Act No. 368 of the Public Acts of 1978, entitled as amended "Public health code,"

section 17401 as amended and sections 17412 and 17749 as added by Act No. 42 of the Public Acts of 1984, being sections 333.17401, 333.17412, 333.17708, and 333.17749 of the Michigan Compiled Laws; to add sections 17435, 17437, and 17750; and to repeal certain parts of the act.

THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

- 1 Section 1. Sections 17401, 17412, 17708, and 17749 of Act
- 2 No. 368 of the Public Acts of 1978, section 17401 as amended and
- 3 sections 17412 and 17749 as added by Act No. 42 of the Public
- 4 Acts of 1984, being sections 333.17401, 333.17412, 333.17708, and
- 5 333.17749 of the Michigan Compiled Laws, are amended and sections
- 6 17435, 17437, and 17750 are added to read as follows:

02609'89 * CPD

- 1 Sec. 17401. (1) As used in this part:
- 2 (a) "Optometrist" means an individual licensed under this
- 3 article to engage in the practice of optometry.
- 4 (b) "Practice of optometry" means 1 or more of the
- 5 following:
- 6 (i) The examination of the human eye to ascertain the pres
- 7 ence of defects or abnormal conditions which may be corrected,
- 8 remedied, or relieved, or the effects of which may be corrected,
- 9 remedied, or relieved by the use of lenses, prisms, or other
- 10 mechanical devices AND RELATED STRUCTURES FOR THE PURPOSE OF
- 11 DIAGNOSIS, TREATMENT, OR REFERRAL FOR CONSULTATION AND TREATMENT
- 12 OF VISUAL DEFECTS, ABNORMAL CONDITIONS, OR DISEASES.
- 13 (ii) The employment of objective or subjective physical
- 14 means to determine the accommodative or refractive conditions or
- 15 the range of powers of vision or muscular equilibrium of the
- 16 human eye- INSTRUMENTS, DEVICES, DIAGNOSTIC PHARMACEUTICAL AGENTS
- 17 AND THERAPEUTIC PHARMACEUTICAL AGENTS, AND NONINVASIVE PROCEDURES
- 18 FOR THE PURPOSE OF INVESTIGATION, EXAMINATION, DIAGNOSIS, TREAT-
- 19 MENT, OR CORRECTION OF VISUAL DEFECTS, ABNORMAL CONDITIONS, OR
- 20 DISEASES OF THE HUMAN EYE AND RELATED STRUCTURES.
- 21 (iii) The adaptation or the adjustment of the lenses or
- 22 prisms to correct, remedy, or relieve a defect or abnormal condi-
- 23 tion or to correct, remedy, or relieve the effect of a defect or
- 24 abnormal condition of the human eye. THE PRESCRIPTION AND APPLI-
- 25 CATION OF LENSES, PRISMS, DEVICES CONTAINING LENSES OR PRISMS,
- 26 ORTHOPTICS, VISUAL THERAPY, DIAGNOSTIC PHARMACEUTICAL AGENTS AND
- 27 THERAPEUTIC PHARMACEUTICAL AGENTS, PROSTHETIC DEVICES, AND OTHER

- 1 NONINVASIVE PROCEDURES FOR THE PURPOSE OF CORRECTION,
- 2 ALLEVIATION, OR TREATMENT OF VISUAL DEFECTS, ABNORMAL CONDITIONS,
- 3 OR DISEASES OF THE HUMAN EYE AND RELATED STRUCTURES.
- 4 (iv) The examination of the human eye for contact lenses and
- 5 the fitting or insertion of contact lenses to the eye.
- 6 -(ν) The employment of objective or subjective means,
- 7 including topical ocular diagnostic pharmaceutical agents by an
- 8 optometrist who meets the requirements of section 17412, for the
- 9 examination of the human eye for the purpose of ascertaining a
- 10 departure from the normal, measuring of powers of vision, and
- 11 adapting lenses for the aid thereof.
- 12 (c) "-Topical ocular diagnostic DIAGNOSTIC pharmaceutical
- 13 agent" means ANY NONINJECTED PHARMACEUTICAL USED FOR THE PURPOSE
- 14 OF ASCERTAINING OR AIDING IN A DIAGNOSIS.
- 15 (i) The following commercially prepared topical
- 16 anesthetic: Proparacaine HCL 0.5%.
- 17 (ii) The following commercially prepared
- 18 cycloplegic/mydriatic: Tropicamide in strength not greater than
- 19 18.
- 20 (D) "THERAPEUTIC PHARMACEUTICAL AGENT" MEANS 1 OR MORE OF
- 21 THE FOLLOWING:
- 22 (i) TOPICALLY ADMINISTERED AGENTS USED FOR THE PURPOSE OF
- 23 TREATING OR ALLEVIATING THE EFFECTS OF DISEASES OR ABNORMAL CON-
- 24 DITIONS OF THE ANTERIOR SEGMENT OF THE HUMAN EYE OR RELATED
- 25 STRUCTURES.
- 26 (ii) ORALLY ADMINISTERED AGENTS USED FOR THE PURPOSE OF
- 27 TREATING OR ALLEVIATING THE EFFECTS OF DISEASES OR ABNORMAL

- 1 CONDITIONS OF THE ANTERIOR SEGMENT OF THE HUMAN EYE OR RELATED
- 2 STRUCTURES.
- 3 (iii) ORALLY ADMINISTERED ANALGESIC AGENTS INCLUDED IN
- 4 SCHEDULES 3 AND 4 UNDER SECTIONS 7215 TO 7218 FOR THE PURPOSE OF
- 5 ALLEVIATING PAIN CAUSED BY DISEASES OR ABNORMAL CONDITIONS OF THE
- 6 ANTERIOR SEGMENT OF THE HUMAN EYE OR RELATED STRUCTURES.
- 7 (E) "NONINVASIVE PROCEDURES" MEANS PROCEDURES USED TO DIAG-
- 8 NOSE OR TREAT A DISEASE OR ABNORMAL CONDITION OF THE ANTERIOR
- 9 SEGMENT OF THE HUMAN EYE OR RELATED STRUCTURES WHICH DO NOT
- 10 REQUIRE AN INCISION OR THERAPEUTIC APPLICATION OF LASERS FOR THE
- 11 TREATMENT OF DISEASE.
- 12 (2) In addition to the definitions in this part, article 1
- 13 contains general definitions and principles of construction
- 14 applicable to all articles in this code and part 161 contains
- 15 definitions applicable to this part.
- 16 Sec. 17412. (1) Subject to subsection (2), a A licensee
- 17 may administer a topical ocular diagnostic pharmaceutical agent
- 18 to the anterior segment of the human eye during an eye
- 19 examination in the course of his or her practice -solely for
- 20 the -purposes- PURPOSE of determining the refractive, muscular,
- 21 or functional origin of sources of visual discomfort or diffi-
- 22 culty and detecting abnormalities which may be evidence
- 23 DIAGNOSIS of disease AND ABNORMAL CONDITIONS if the licensee is
- 24 certified by the Michigan board of optometry as being qualified
- 25 to administer -topical ocular diagnostic pharmaceutical agents
- 26 pursuant to this section.

- 1 (2) The topical anesthetic described in section
- 2 17401(1)(c)(i) shall be utilized only in diagnostic procedures
- 3 which aid in detecting glaucoma.
- 4 (2) -(3) The Michigan board of optometry shall certify a
- 5 licensee as qualified to administer topical ocular diagnostic
- 6 pharmaceutical agents if the licensee meets all of the following
- 7 requirements:
- 8 (a) Has successfully completed 60 classroom hours of study
- 9 in general and clinical pharmacology as it relates to the prac-
- 10 tice of optometry, with particular emphasis on the use of
- 11 -topical ocular diagnostic pharmaceutical agents for examination
- 12 purposes. Not less than 30 of the 60 classroom hours shall be in
- 13 ocular pharmacology and shall emphasize the systemic effects of
- 14 and reactions to -topical ocular diagnostic pharmaceutical
- 15 agents, including the emergency management and referral of any
- 16 adverse reactions that may occur. The course of study shall be
- 17 approved by the Michigan board of optometry, and shall be offered
- 18 by a school or college of optometry -which THAT is recognized by
- 19 the Michigan board of optometry as fully accredited. The course
- 20 of study shall be completed before taking the examination
- 21 required by this section.
- 22 (b) Has successfully completed an examination approved by
- 23 the Michigan board of optometry on the subject of general and
- 24 ocular pharmacology as it relates to the practice of optometry
- 25 with particular emphasis on the use of topical ocular diagnos-
- 26 tic pharmaceutical agents, including emergency management and
- 27 referral of any adverse reactions that may occur.

- (c) Has successfully completed a course in cardiopulmonary
- 2 resuscitation APPROVED BY THE DEPARTMENT AND offered or approved
- 3 by the red cross, American heart association, an accredited hos-
- 4 pital, or a comparable organization or institution.
- 5 (d) Has established an emergency plan for the management and
- 6 referral to appropriate medical services of patients who -may-
- 7 experience adverse drug reactions resulting from the application
- 8 of topical ocular diagnostic pharmaceutical agents. The plan
- 9 shall be approved by the Michigan board of optometry and shall,
- 10 at a minimum, require the optometrist to do all of the
- 11 following:
- 12 (i) Refer patients who notify the optometrist of an adverse
- 13 drug reaction to appropriate medical specialists or facilities.
- 14 (ii) Routinely advise each patient to immediately contact
- 15 the optometrist if the patient experiences an adverse drug
- 16 reaction.
- 17 (iii) Place in the patient's permanent record information
- 18 describing any adverse drug reaction experienced by the patient,
- 19 and the date and time that any referral was made.
- 20 (iv) Include in the plan the names of not less than 3 physi-
- 21 cians, physician clinics, or hospitals to whom the optometrist
- 22 will refer patients who experience an adverse drug reaction. At
- 23 least 1 of the physicians, physician clinics, or hospitals shall
- 24 be skilled or shall specialize in the diagnosis and treatment of
- 25 diseases of the eye. As used in this subparagraph, "physician"
- 26 means a physician as defined in section 17001 or 17501.

(e) Has paid the certification fee to administer topical 2 ocular diagnostic pharmaceutical agents prescribed in section 61 3 of the state license fee act, Act No. 152 of the Public Acts of 4 1979, being section 338.2261 of the Michigan Compiled Laws. (3) -(4) The course of study and examination required by 5 6 subsection -(3) (2)(a) and (b) shall be completed prior to 7 certification, except that the Michigan board of optometry may 8 certify applicants who have graduated from a school of optometry 9 recognized by the Michigan board of optometry as accredited 10 within the 5 years immediately preceding the effective date of 11 this section ON OR AFTER APRIL 12, 1979, if the school's curric-12 ulum includes a course of study and examination meeting the 13 requirements of subsection $\frac{(3)(a)}{(2)(A)}$ (2)(A) and (b). (5) Approvals of the course of study, examination, and 15 emergency plan required by subsection (3)(a), (b), and (d) shall 16 be given by the Michigan board of optometry only after consulta-17 tion with the Michigan board of medicine, the Michigan board of 18 osteopathic medicine and surgery, and the Michigan board of 19 pharmacy. The recommendations of the Michigan board of medicine, 20 the Michigan board of osteopathic medicine and surgery, and the 21 Michigan board of pharmacy shall be made within 120 days after 22 they are requested by the Michigan board of optometry. 23 (6) An optometrist shall not purchase, possess, administer,

24 prescribe, or give any prescription drug as defined in section

26 as expressly authorized by this section.

25 17708 or a topical ocular diagnostic pharmaceutical agent except

- 1 SEC. 17435. (1) A LICENSEE MAY ADMINISTER AND PRESCRIBE
- 2 THERAPEUTIC PHARMACEUTICAL AGENTS IN THE COURSE OF HIS OR HER
- 3 PRACTICE IF THE LICENSEE IS CERTIFIED BY THE MICHIGAN BOARD OF
- 4 OPTOMETRY AS BEING QUALIFIED TO ADMINISTER AND PRESCRIBE THERA-
- 5 PEUTIC PHARMACEUTICAL AGENTS PURSUANT TO THIS SECTION.
- 6 (2) THE MICHIGAN BOARD OF OPTOMETRY SHALL CERTIFY A LICENSEE
- 7 AS OUALIFIED TO ADMINISTER AND PRESCRIBE THERAPEUTIC PHARMACEUTI-
- 8 CAL AGENTS IF THE LICENSEE MEETS ALL OF THE FOLLOWING
- 9 REQUIREMENTS:
- 10 (A) HAS BEEN CERTIFIED BY THE MICHIGAN BOARD OF OPTOMETRY TO
- 11 ADMINISTER DIAGNOSTIC PHARMACEUTICAL AGENTS.
- 12 (B) HAS SUCCESSFULLY EARNED AT LEAST 10 QUARTER HOURS OF
- 13 CREDIT OR SUCCESSFULLY COMPLETED 100 CLASSROOM HOURS OF STUDY IN
- 14 COURSES RELATING TO THE DIDACTIC AND CLINICAL USE OF THERAPEUTIC
- 15 PHARMACEUTICAL AGENTS FROM A SCHOOL OR COLLEGE OF OPTOMETRY THAT
- 16 IS RECOGNIZED BY THE MICHIGAN BOARD OF OPTOMETRY AS FULLY ACCRED-
- 17 ITED OR HAS SUCCESSFULLY COMPLETED AN EXAMINATION APPROVED BY THE
- 18 MICHIGAN BOARD OF OPTOMETRY ON THE SUBJECT OF TREATMENT AND MAN-
- 19 AGEMENT OF OCULAR DISEASE.
- 20 (C) HAS PAID ALL NECESSARY FEES PRESCRIBED IN SECTION 2261
- 21 OF THE STATE LICENSE FEE ACT, ACT NO. 152 OF THE PUBLIC ACTS OF
- 22 1979, BEING SECTION 338.2261 OF THE MICHIGAN COMPILED LAWS.
- 23 SEC. 17437. AN OPTOMETRIST LICENSED AFTER THE EFFECTIVE
- 24 DATE OF THIS SECTION SHALL OBTAIN CERTIFICATION TO ADMINISTER
- 25 DIAGNOSTIC PHARMACEUTICAL AGENTS OR TO ADMINISTER AND PRESCRIBE
- 26 THERAPEUTIC PHARMACEUTICAL AGENTS AT THE TIME OF INITIAL
- 27 LICENSURE.

- 1 Sec. 17708. (1) "Preceptor" means a pharmacist approved by 2 the board to direct the training of an intern in an approved 3 pharmacy.
- 4 (2) "Prescriber" means a licensed dentist, doctor of medi-5 cine, doctor of osteopathic medicine and surgery, doctor of podi-
- 6 atric medicine and surgery, OPTOMETRIST, veterinarian, or other
- 7 licensed health professional acting under the delegation and
- 8 using, recording, or otherwise indicating the name of the dele-
- 9 gating licensed doctor of medicine or doctor of osteopathic medi-10 cine and surgery.
- 11 (3) "Prescription" means an order for drugs or devices writ-
- 12 ten and signed or transmitted by other means of communication by
- 13 a prescriber to be filled, compounded, or dispensed. Prescribing
- 14 shall be limited to a prescriber. An order transmitted in other
- 15 than written form shall be recorded or written and immediately
- 16 dated by the pharmacist, and that record constitutes the original
- 17 prescription. In a medical institution an order for drugs or
- 18 devices in the patient's chart constitutes for the purposes of
- 19 this definition the original prescription.
- 20 (4) "Prescription drug" means any of the following:
- 21 (a) A drug dispensed pursuant to a prescription.
- (b) A drug bearing the federal legend "CAUTION: federal law
- 23 prohibits dispensing without prescription".
- 24 (c) A drug designated by the board as one which may only be
- 25 dispensed pursuant to a prescription.
- 26 Sec. 17749. (1) Notwithstanding any provision of this act
- 27 or any rule promulgated under this act, a wholesale distributor

- 1 or pharmacist may dispense a -topical-ocular diagnostic
- 2 pharmaceutical agent to a licensed optometrist for subsequent
- 3 administration to optometric patients, if the optometrist pro-
- 4 vides the wholesale distributor or pharmacist with the number of
- 5 the optometrist's certification of qualification to administer
- 6 topical ocular diagnostic pharmaceutical agents.
- 7 (2) As used in this section, "topical ocular "diagnostic
- 8 pharmaceutical agent" means that term as defined in section
- 9 17401.
- 10 SEC. 17750. (1) A PHARMACIST MAY DISPENSE A PRESCRIPTION
- 11 FOR A THERAPEUTIC PHARMACEUTICAL AGENT ISSUED BY AN OPTOMETRIST
- 12 CERTIFIED BY THE MICHIGAN BOARD OF OPTOMETRY AS QUALIFIED TO PRE-
- 13 SCRIBE AND ADMINISTER THERAPEUTIC PHARMACEUTICAL AGENTS.
- 14 (2) AS USED IN THIS SECTION, "THERAPEUTIC PHARMACEUTICAL
- 15 AGENT" MEANS THAT TERM AS DEFINED IN SECTION 17401.
- 16 Section 2. Sections 17432 and 17433 of Act No. 368 of the
- 17 Public Acts of 1978, being sections 333.17430 and 333.17433 of
- 18 the Michigan Compiled Laws, are repealed.